Identification of EEF1A1 as a therapeutic target in TNBC: Anticancer action of a novel Penicillide-derived inhibitor through ribosomal protein regulation
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2026.109602 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Jing Yu und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Quality and Safety of Agro-products, School of Marine Sciences, Ningbo University, Ningbo 315211, Zhejiang, China; Laborator…. Hauptthemen laut MEDLINE: Peptide Elongation Factor 1, Antineoplastic Agents, Triple Negative Breast Neoplasms, Ribosomal Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: Science and Technology Innovation 2025 Major Project of Ningbo Municipality, Natural Science Foundation of Zhejiang Province, Natural Science Foundation of Ningbo Municipality.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is one of the most prevalent and aggressive subtypes of breast cancer worldwide, contributing significantly to cancer-related mortality in women. Due to the absence of effective targeted therapies, there is an urgent need to identify novel molecular targets and bioactive compounds for TNBC treatment. Eukaryotic elongation factor 1A1 (EEF1A1), a key regulator of protein synthesis through its role in peptide chain elongation, has emerged as a potential therapeutic candidate; however, its functional role in TNBC remains poorly understood. In this study, we isolated a series of Penicillide-like compounds from the mycelium of Penicillium sp. NBU2256, designated as compounds 1-5. Using CCK-8 cytotoxicity assays, compound 2 was identified as the most potent inhibitor of TNBC cell viability. Subsequent mechanistic investigations revealed that compound 2 induced apoptosis, triggered cell cycle arrest, and modulated cancer stem cell properties. To elucidate its molecular target, we employed drug affinity responsive target stability (DARTS) and cellular thermal shift assay (CETSA), which identified EEF1A1 as a direct binding partner of compound 2. Network pharmacology analysis further predicted RPL27A and RPLP0 as downstream effectors of EEF1A1 signaling. Functional validation using actinomycin D and cycloheximide treatments demonstrated that compound 2 suppresses RPL27A and RPLP0 expression at the translational level, thereby inhibiting tumor cell invasion and migration and exerting robust antitumor effects. Collectively, these findings provide novel insights into the anticancer mechanisms of EEF1A1-targeting agents and highlight EEF1A1 as a promising therapeutic target for the treatment of TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Quality and Safety of Agro-products, School of Marine Sciences, Ningbo University, Ningbo 315211, Zhejiang, China; Laboratory of Biochemistry and Molecular Biology, School of Marine Sciences, Me…
- School of Pharmacy, Health Science Center, Ningbo University, Ningbo 315211, China.
- School of Pharmacy, Health Science Center, Ningbo University, Ningbo 315211, China. Electronic address: dinglijian@nbu.edu.cn.
Förderung
- Science and Technology Innovation 2025 Major Project of Ningbo Municipality
- Natural Science Foundation of Zhejiang Province
- Natural Science Foundation of Ningbo Municipality
- Ningbo University
Zitieren
APA
Yu, J., Chen, R. Y., Liu, Y. J., Feng, F. J., Li, Y. J., Hu, Y. J., Yang, G. J., Chen, J., & Ding, L. J. (2026). Identification of EEF1A1 as a therapeutic target in TNBC: Anticancer action of a novel Penicillide-derived inhibitor through ribosomal protein regulation. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.109602
Vancouver
Yu J, Chen RY, Liu YJ, Feng FJ, Li YJ, Hu YJ, et al. Identification of EEF1A1 as a therapeutic target in TNBC: Anticancer action of a novel Penicillide-derived inhibitor through ribosomal protein regulation. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.109602
BibTeX
@article{Yu2026,
author = {Yu, Jing and Chen, Ru-Yi and Liu, Yan-Jun and Feng, Fang-Jian and Li, Yu-Jia and Hu, Yan-Jie and Yang, Guan-Jun and Chen, Jiong and Ding, Li-Jian},
title = {Identification of EEF1A1 as a therapeutic target in TNBC: Anticancer action of a novel Penicillide-derived inhibitor through ribosomal protein regulation},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2026.109602}
}
EUVIMED